NSE ScannerHospitals & Diagnostics · Medical/Nursing Services · NSE: LALPATHLAB · data 2026-10-31
Dr. Lal PathLabs Limited
In plain words
Price: 6.5% below its 52-week high of ₹2,038.6.
Delivery: 65.5% of traded shares were kept for delivery over the last 10 sessions, against 57.0% over the last 60.
Latest results: a net profit of ₹170 cr for the quarter ended Jun 2026 (+28.0% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹2,891 cr |
| Net profit (last 12 months) | ₹542 cr |
| Sales growth, 3 years (yearly) | 11.1% |
| Profit growth, 3 years (yearly) | 28.3% |
At a glance
Promoters 52.9% (-0.3 pts in a year), pledged 0.0%, institutions 40.3%.
P/E 58.9, dividend yield 0.8%. Price relative to earnings and book value (low is cheaper, not better).
ROE 21.6%, ROCE 25.3%, operating margin 23.0%: how much profit it earns on the money it uses.
Debt/equity 0.08, Profit growth 28.3% and sales growth 11.1% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Virtually debt-free (debt/equity 0.1 or less).
- High return on equity (21.6%).
- Healthy operating margin (23.0%).
- Profit grew 28.3% a year over 3 years.
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q1 FY27)
LALPATHLAB Q1 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹797.7 crore, up 19.1% YoY and up 13.5% QoQ.
Net profit was ₹169.5 crore, up 28% YoY and up 29.1% QoQ.
Operating margin was 31% (28.7% a year ago).
EPS was ₹10.15, up 28% YoY and up 29.1% QoQ.
LALPATHLAB के Q1 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹797.7 करोड़; पिछले साल की तुलना में 19.1% की बढ़त, पिछली तिमाही की तुलना में 13.5% की बढ़त।
शुद्ध मुनाफ़ा: ₹169.5 करोड़; पिछले साल की तुलना में 28% की बढ़त, पिछली तिमाही की तुलना में 29.1% की बढ़त।
ऑपरेटिंग मार्जिन: 31% (एक साल पहले 28.7%)।
EPS: ₹10.15; पिछले साल की तुलना में 28% की बढ़त, पिछली तिमाही की तुलना में 29.1% की बढ़त।
LALPATHLABના Q1 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹797.7 કરોડ; ગયા વર્ષની સરખામણીએ 19.1% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 13.5% વધારો.
ચોખ્ખો નફો: ₹169.5 કરોડ; ગયા વર્ષની સરખામણીએ 28% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 29.1% વધારો.
ઓપરેટિંગ માર્જિન: 31% (એક વર્ષ પહેલાં 28.7%).
EPS: ₹10.15; ગયા વર્ષની સરખામણીએ 28% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 29.1% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
36/100 · Neutral over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 10/30: Delivery 61.4% over the last 20 sessions vs 49.7% in the 40 before (1.24x); shares delivered per day 1.14x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 13/15: 23 schemes hold it, about ₹1,737 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 8/15: Verdict "Building", sustained score 58/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Dividend ● Results ● Bonus
- 30 Jul 26Dividend Dividend ₹5 (ex-date) +1.2% next session
- 24 Jul 26Results Q1 FY27 results: profit +28.0% YoY +8.3% next session
- 25 Jun 26Dividend Dividend ₹4 (ex-date) -0.8% next session
- 30 Apr 26Results Q4 FY26 results: profit −15.2% YoY +12.6% next session
- 5 Feb 26Dividend Dividend ₹3.5 (ex-date) +2.6% next session
- 30 Jan 26Results Q3 FY26 results: profit −6.4% YoY
- 19 Dec 25Bonus Bonus 1:1 (ex-date)
- 7 Nov 25Dividend Dividend ₹7 (ex-date) -0.6% next session
- 31 Oct 25Results Q2 FY26 results: profit +16.6% YoY +5.4% next session
- 6 Aug 25Dividend Dividend ₹6 (ex-date) +0.6% next session
- 31 Jul 25Results Q1 FY26 results: profit +24.4% YoY +2.5% next session
- 6 Jun 25Dividend Dividend ₹6 (ex-date) +0.6% next session
- 25 Apr 25Results Q4 FY25 results: profit +83.2% YoY +0.8% next session
- 5 Feb 25Dividend Dividend ₹6 (ex-date) -0.9% next session
- 30 Jan 25Results Q3 FY25 results: profit +18.9% YoY +3.4% next session
- 5 Nov 24Dividend Dividend ₹6 (ex-date) +0.9% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹798 cr | ₹170 cr | +28.0% | 31.0% | 10.15 |
| Mar 2026 | ₹703 cr | ₹131 cr | -15.2% | 26.6% | 7.86 |
| Dec 2025 | ₹660 cr | ₹91 cr | -6.4% | 27.2% | 5.42 |
| Sept 2025 | ₹731 cr | ₹151 cr | +16.6% | 30.7% | 18.05 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 52.93% | 53.19% | 53.21% | 53.21% |
| Foreign institutions (FII) | 18.73% | 17.36% | 17.18% | 20.29% |
| Domestic institutions (DII) | 21.58% | 21.59% | 21.38% | 19.21% |
| Mutual funds | 18.68% | 18.79% | 18.62% | 16.84% |
| Retail investors | 4.00% | 4.97% | 5.20% | 4.56% |
| Number of shareholders | 1,13,559 | 1,11,037 | 1,14,527 | 1,16,167 |
Common questions
What was Dr. Lal PathLabs Limited's latest quarterly profit?
Dr. Lal PathLabs Limited reported a net profit of ₹170 cr for the quarter ended Jun 2026 (+28.0% on the same quarter a year earlier), on revenue of ₹798 cr.
How much do promoters hold in Dr. Lal PathLabs Limited?
Promoters held 52.93% of Dr. Lal PathLabs Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Dr. Lal PathLabs Limited debt-free?
Its latest reported debt-to-equity ratio is 0.08, which is very low.
What is Dr. Lal PathLabs Limited's P/E ratio?
About 58.9, based on the last 12 months' earnings and a price of ₹1,906.4 (data 2026-10-31).
What is the 52-week high and low of Dr. Lal PathLabs Limited?
The 52-week high is ₹2,038.6 and the 52-week low is ₹1,272.6.
Mutual funds holding Dr. Lal PathLabs Limited
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 23 schemes holding about ₹1,737 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| ADITYA BIRLA SUN LIFE FLEXI CAP FUND | Aditya Birla Sun Life Mutual Fund | 1.67% | ₹467 cr |
| SBI Large and Midcap Fund | SBI Mutual Fund | 0.64% | ₹259 cr |
| NIPPON INDIA PHARMA FUND | Nippon India Mutual Fund | 2.17% | ₹199 cr |
| Mirae Asset Small Cap Fund | Mirae Asset Mutual Fund | 2.30% | ₹134 cr |
| SBI Dividend Yield Fund | SBI Mutual Fund | 1.63% | ₹131 cr |
| ADITYA BIRLA SUN LIFE SMALL CAP FUND | Aditya Birla Sun Life Mutual Fund | 2.03% | ₹124 cr |
| Mirae Asset Healthcare Fund | Mirae Asset Mutual Fund | 2.90% | ₹101 cr |
| SBI Healthcare Opportunities Fund | SBI Mutual Fund | 1.62% | ₹95 cr |
| ADITYA BIRLA SUN LIFE MIDCAP FUND | Aditya Birla Sun Life Mutual Fund | 1.22% | ₹80 cr |
| ADITYA BIRLA SUN LIFE PHARMA & HEALTHCARE FUND | Aditya Birla Sun Life Mutual Fund | 3.51% | ₹38 cr |
| Nippon India Nifty Smallcap 250 Index Fund | Nippon India Mutual Fund | 0.69% | ₹24 cr |
| Mirae Asset Multi Asset Allocation Fund | Mirae Asset Mutual Fund | 0.48% | ₹17 cr |
| Mirae Asset Nifty Smallcap 250 Momentum Quality 100 ETF | Mirae Asset Mutual Fund | 1.69% | ₹16 cr |
| SBI Nifty Smallcap 250 Index Fund | SBI Mutual Fund | 0.69% | ₹12 cr |
| ADITYA BIRLA SUN LIFE RETIREMENT FUND - THE 30S PLAN | Aditya Birla Sun Life Mutual Fund | 2.37% | ₹11 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Dr. Lal PathLabs Limited | ₹1,906.4 | ₹31,997 cr | 58.9 | — | 21.6% | 25.3% | 0.08 | +23.7% |
| Dr. Agarwal's Health Care Ltd. | ₹509.2 | ₹16,116 cr | 109.5 | — | 6.8% | 9.1% | 0.53 | -1.4% |
| Vijaya Diagnostic Centre Ltd. | ₹1,445.7 | ₹14,906 cr | 79.5 | — | 19.7% | 19.6% | 0.44 | +43.3% |
| Metropolis Healthcare Ltd. | ₹545.65 | ₹11,309 cr | 56.2 | — | 13.4% | 16.3% | 0.15 | +12.3% |
| Thyrocare Technologies Ltd | ₹456.3 | ₹7,274 cr | 51 | 13.1 | 28.8% | 34.2% | 0.09 | +1.5% |
| Nephrocare Health Services Limited | ₹614.55 | ₹6,194 cr | — | — | 9% | 14.6% | 0.07 | +25.4% |
Compare LALPATHLAB with AGARWALEYE in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open LALPATHLAB in NSE Scanner →